Dal, Mehmet SinanUlu, Bahar UncuUzay, AntAkay, Olga MeltemBesisik, SevgiYenerel, Mustafa NuriCelik, SerhatKaynar, LeylagulYucel, Orhan KemalDeveci, BurakSonmez, MehmetMehtap, OzgurBekoz, Huseyin SaffetSunu, CenkSalim, OzanUlas, TurgayKarti, SamiAltuntas, FevziFerhanoglu, BurhanTuglular, Tulin Firat2023-02-212023-02-212023-01-0110.1007/s00277-022-05052-xhttps://hdl.handle.net/11443/2767http://dx.doi.org/10.1007/s00277-022-05052-xPolatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9\%, including 32.4\% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.Diffuse large B-cell lymphomaPolatuzumab vedotinRefractoryRelapsedRituximabBendamustineArticleWOS:000885401400002